WA-KYMETA
23.3.2022 14:02:14 CET | Business Wire | Press release
Kymeta (www.kymetacorp.com ), the communications company making mobile global, and IP Access International (www.ipinternational.net ), a leading mobile and fixed satellite solutions provider, announced today the signing of a partnership agreement to co-develop and distribute optimized solutions using Kymeta terminals, broadband and LTE services to first responders across North America.
Today, IP Access operates the nation’s largest public safety satellite network, which includes over 1,000 agency customers encompassing 1,700 unique endpoints. This agreement to deliver optimized solutions will combine Kymeta’s resilient and cost-effective electronically-steered flat panel technology with IP Access’ experience building public safety networks for mobility and remote connectivity where it has not previously existed. It will utilize coverage and bandwidth on a jointly developed, multi layered broadband network optimized specifically for public safety customers. The Kymeta enabled solution allows communication and interoperability among devices, further extending the reach of the IP Access RedPHONE service even if there is an internet outage due to malware or denial-of-service attacks.
“Kymeta is dedicated to bringing access to always-on, reliable, and mission-critical communications while on the move to the public safety and first responder market,” said Bill Marks, EVP and Chief Development Officer of Kymeta. “Our u8 products have been deployed around the world and provide a real-world solution for the defense, government, public safety, and commercial industries by enabling connectivity that is ubiquitous and more robust than ever before. We are pleased to partner with a well-established leader like IP Access who has earned the continued trust and loyalty of first responders for over two decades through the delivery of consistent, reliable products and services.”
“IP Access looks forward to a strong partner relationship with Kymeta in our joint efforts to provide resilient communications to response teams who protect and save lives,” said Bryan Hill, CEO of IP Access International. “Our customers are indifferent to what network they are on so long as it is reliable. Our goal at IP Access is to provide them with the connectivity they need on every possible network. That means 4G, 5G, GEO, MEO and LEO. Customers have capital constraints, and it is our responsibility to deliver solutions that are future proof and that is why we are partnering with Kymeta.”
The Kymeta u8 product family for mobile broadband communications are low-maintenance and low-profile for resilient communications-on-the-move (COTM) and communications-on-the-pause (COTP). The u8 product family also offers a pathway to low Earth orbit (LEO) networks as they come online over the next several years. The new partnership will allow IP Access to provide solutions that perform on today’s satellites and are enabled to work on future LEO satellite networks.
The partnership illustrates the commitment from both companies to enable critical mobile connectivity solutions for public safety and for disaster response that are more robust than ever before. Kymeta and IP Access have committed to a significant volume of equipment and satellite bandwidth to quickly fulfill the needs of public safety and first responders and grow the product suite and coverage in support of this important market.
About Kymeta
Kymeta is the leader in unlocking the potential of broadband satellite connectivity, combined with cellular networks, to satisfy the overwhelming demand for communications-on-the-move and making mobile global. Kymeta satellite connectivity solutions offer unique, complete, and turnkey bundled solutions to the market based on best-in-class technologies and tailored customer-centric services that meet and exceed customer mission requirements. These solutions, in tandem with the company’s flat-panel satellite antenna, the first of its kind, and Kymeta services provide revolutionary mobile connectivity on satellite and hybrid satellite-cellular networks to customers around the world. Backed by U.S. and international patents and licenses, the Kymeta terminal addresses the need for low-power, low-cost, and high-throughput communication systems that have no moving parts. Kymeta makes connecting easy – for any vehicle, vessel, aircraft, or fixed platform.
Kymeta is a privately held company based in Redmond, Washington.
For more information, visit kymetacorp.com
About IP Access International
IP Access is a leading provider of mobile and fixed satellite internet solutions with over 20 years experience serving the satellite industry as a domestic and global provider. IP Access provides complete satellite communications solutions inclusive of satellite network offerings, terminal hardware, and installation and support services. Incorporated in 1999, today IP Access operates the nation’s largest satellite network of public safety agencies, which includes over 1000 agency customers encompassing 1,700 unique endpoints. At the heart of the IP Access offering is the SELECT Network, providing multiple satellite options and multiple teleports, ensuring protection against regional disasters and infrastructure disruptions while also allowing for on-demand user selectable satellite service in the event of line-of-sight or look angle obstructions.
For more information, visit ipinternational.net
View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005277/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom